Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct;83(8):1102–1109. doi: 10.1054/bjoc.2000.1400

Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells

R M Sharrard 1, N J Maitland 1
PMCID: PMC2363557  PMID: 10993660

Abstract

The prostate cancer cell lines PC3 and LNCaP have been shown to lack expression of the tumour suppressor gene MMAC1/PTEN, in contrast to the immortalized non-tumorigenic epithelial lines PNT1a and PNT2. We have measured the effects of reintroduction of wild type (wt) and mutant MMAC1 genes on to these genetic backgrounds, using gene constructs expressing either wt MMAC1 or various mutants deficient in the dual specificity phosphatase domain of the protein. Over-expression of wild type PTEN protein induced cell shrinkage and rounding, but did not result in increased levels of classical apoptosis. Permanently transfected lines containing the MMAC1 gene could only be obtained from the PNT cells, as PTEN expression resulted in rapid loss of both tumour lines. In contrast, mutation of the phosphatase domain resulted in partial attenuation of the phenotypic effects of MMAC1 after transient transfection, and also allowed the derivation of permanent tumour cell lines containing the mutated MMAC1 gene. The results suggest that re-expression of wt PTEN is incompatible with survival of human prostate cancer cells in vitro, and that the full biological activity of this common tumour suppressor requires functions additional to the established protein and lipid phosphatase activities in epithelial systems. © 2000 Cancer Research Campaign

Keywords: prostate cancer, MMAC1/PTEN/TEP1, cell survival, cell morphology

Full Text

The Full Text of this article is available as a PDF (398.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergerheim U. S., Kunimi K., Collins V. P., Ekman P. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer. 1991 May;3(3):215–220. doi: 10.1002/gcc.2870030308. [DOI] [PubMed] [Google Scholar]
  2. Boström J., Cobbers J. M., Wolter M., Tabatabai G., Weber R. G., Lichter P., Collins V. P., Reifenberger G. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998 Jan 1;58(1):29–33. [PubMed] [Google Scholar]
  3. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J. G., Jen J., Isaacs W. B., Bova G. S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997 Nov 15;57(22):4997–5000. [PubMed] [Google Scholar]
  4. Cheney I. W., Johnson D. E., Vaillancourt M. T., Avanzini J., Morimoto A., Demers G. W., Wills K. N., Shabram P. W., Bolen J. B., Tavtigian S. V. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 1998 Jun 1;58(11):2331–2334. [PubMed] [Google Scholar]
  5. Cheney I. W., Neuteboom S. T., Vaillancourt M. T., Ramachandra M., Bookstein R. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res. 1999 May 15;59(10):2318–2323. [PubMed] [Google Scholar]
  6. Cussenot O., Berthon P., Berger R., Mowszowicz I., Faille A., Hojman F., Teillac P., Le Duc A., Calvo F. Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J Urol. 1991 Sep;146(3):881–886. doi: 10.1016/s0022-5347(17)37953-3. [DOI] [PubMed] [Google Scholar]
  7. Davies M. A., Koul D., Dhesi H., Berman R., McDonnell T. J., McConkey D., Yung W. K., Steck P. A. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res. 1999 Jun 1;59(11):2551–2556. [PubMed] [Google Scholar]
  8. Davies M. A., Lu Y., Sano T., Fang X., Tang P., LaPushin R., Koul D., Bookstein R., Stokoe D., Yung W. K. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998 Dec 1;58(23):5285–5290. [PubMed] [Google Scholar]
  9. Dong J. T., Sipe T. W., Hyytinen E. R., Li C. L., Heise C., McClintock D. E., Grant C. D., Chung L. W., Frierson H. F., Jr PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene. 1998 Oct 15;17(15):1979–1982. doi: 10.1038/sj.onc.1202119. [DOI] [PubMed] [Google Scholar]
  10. Frisch S. M., Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997 Oct;9(5):701–706. doi: 10.1016/s0955-0674(97)80124-x. [DOI] [PubMed] [Google Scholar]
  11. Furnari F. B., Huang H. J., Cavenee W. K. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 1998 Nov 15;58(22):5002–5008. [PubMed] [Google Scholar]
  12. Furnari F. B., Lin H., Huang H. S., Cavenee W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12479–12484. doi: 10.1073/pnas.94.23.12479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Georgescu M. M., Kirsch K. H., Akagi T., Shishido T., Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182–10187. doi: 10.1073/pnas.96.18.10182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gray I. C., Phillips S. M., Lee S. J., Neoptolemos J. P., Weissenbach J., Spurr N. K. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 1995 Nov 1;55(21):4800–4803. [PubMed] [Google Scholar]
  15. Gray I. C., Stewart L. M., Phillips S. M., Hamilton J. A., Gray N. E., Watson G. J., Spurr N. K., Snary D. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer. 1998 Nov;78(10):1296–1300. doi: 10.1038/bjc.1998.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997 Sep 1;57(17):3660–3663. [PubMed] [Google Scholar]
  17. Ittmann M. Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res. 1996 May 1;56(9):2143–2147. [PubMed] [Google Scholar]
  18. Latil A., Lidereau R. Genetic aspects of prostate cancer. Virchows Arch. 1998 May;432(5):389–406. doi: 10.1007/s004280050183. [DOI] [PubMed] [Google Scholar]
  19. Lee J. O., Yang H., Georgescu M. M., Di Cristofano A., Maehama T., Shi Y., Dixon J. E., Pandolfi P., Pavletich N. P. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999 Oct 29;99(3):323–334. doi: 10.1016/s0092-8674(00)81663-3. [DOI] [PubMed] [Google Scholar]
  20. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  21. Macintosh C. A., Stower M., Reid N., Maitland N. J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 1998 Jan 1;58(1):23–28. [PubMed] [Google Scholar]
  22. Maehama T., Dixon J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998 May 29;273(22):13375–13378. doi: 10.1074/jbc.273.22.13375. [DOI] [PubMed] [Google Scholar]
  23. Maier D., Jones G., Li X., Schönthal A. H., Gratzl O., Van Meir E. G., Merlo A. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res. 1999 Nov 1;59(21):5479–5482. [PubMed] [Google Scholar]
  24. Myers M. P., Pass I., Batty I. H., Van der Kaay J., Stolarov J. P., Hemmings B. A., Wigler M. H., Downes C. P., Tonks N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513–13518. doi: 10.1073/pnas.95.23.13513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Myers M. P., Stolarov J. P., Eng C., Li J., Wang S. I., Wigler M. H., Parsons R., Tonks N. K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052–9057. doi: 10.1073/pnas.94.17.9052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pesche S., Latil A., Muzeau F., Cussenot O., Fournier G., Longy M., Eng C., Lidereau R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene. 1998 Jun 4;16(22):2879–2883. doi: 10.1038/sj.onc.1202081. [DOI] [PubMed] [Google Scholar]
  27. Ramaswamy S., Nakamura N., Vazquez F., Batt D. B., Perera S., Roberts T. M., Sellers W. R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2110–2115. doi: 10.1073/pnas.96.5.2110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rees S., Coote J., Stables J., Goodson S., Harris S., Lee M. G. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques. 1996 Jan;20(1):102-4, 106, 108-10. doi: 10.2144/96201st05. [DOI] [PubMed] [Google Scholar]
  29. Rhei E., Kang L., Bogomolniy F., Federici M. G., Borgen P. I., Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997 Sep 1;57(17):3657–3659. [PubMed] [Google Scholar]
  30. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  31. Suzuki H., Freije D., Nusskern D. R., Okami K., Cairns P., Sidransky D., Isaacs W. B., Bova G. S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998 Jan 15;58(2):204–209. [PubMed] [Google Scholar]
  32. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K. M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998 Jun 5;280(5369):1614–1617. doi: 10.1126/science.280.5369.1614. [DOI] [PubMed] [Google Scholar]
  33. Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997 Sep 15;57(18):3935–3940. [PubMed] [Google Scholar]
  34. Trybus T. M., Burgess A. C., Wojno K. J., Glover T. W., Macoska J. A. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res. 1996 May 15;56(10):2263–2267. [PubMed] [Google Scholar]
  35. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995 Jul 17;184(1):39–51. doi: 10.1016/0022-1759(95)00072-i. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES